Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Atugen and metaGen sign target validation agreement

Feb. 19, 2003

Humanized MAbs targeting CEA available for licensing from NIH

Feb. 19, 2003

New data on the antitumor efficacy and toxicity of S-16020-2 in refractory tumors

Feb. 18, 2003

Introgen to pursue registration plans for Advexin in NSCLC

Feb. 18, 2003

Phase III atrasentan study fails to meet primary endpoint in end-stage prostate cancer

Feb. 18, 2003

Wilex and San Raffaele sign cleaved uPA receptor agreement

Feb. 18, 2003

Targeted chemotherapy of endometrial and ovarian cancers with cytotoxic LHRH analogue

Feb. 18, 2003

Antitumor antibiotic isolated by Nippon Kayaku scientists

Feb. 18, 2003

New protein kinase inhibitors covered by Aventis patent

Feb. 18, 2003

Phase I StemEx trial begins patient enrollment

Feb. 17, 2003

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...